Drug Trial Radar · NCT05723692
A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Feb 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Jan 17, 2023
Primary completion
Oct 27, 2023
Study completion Oct 27, 2023
Sponsor
- Lead sponsor
- AltruBio Inc.Industry
- Sponsor type
- Industry
- Collaborators
- ICON plc
- First posted
- Feb 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study with ALTB-268 will determine the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of ALTB-268 in healthy volunteers.
Conditions
- Healthy Volunteers
Interventions
ALTB-268Biological
monoclonal antibody
PlaceboOther
formulation buffer
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of ALTB-268 Treatment-Emergent Adverse EventsTime frame: through study completion, up to day 120 of the study
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ICON Early Development Services
Lenexa, Kansas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.